Answers are grounded in this paper and cite their sources.
Non-response was common in patients with AD who required systemic treatment, and non-response indicators occurred significantly more frequently with SIS treatment than with dupilumab treatment.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: